Bacterial Infection as an Adverse Effect of Telaprevir-based Triple Therapy for Chronic Hepatitis C Infection
-
- Kawano Akira
- Department of Internal Medicine, Kitakyushu Municipal Medical Center, Japan
-
- Ogawa Eiichi
- Department of General Internal Medicine, Kyushu University Hospital, Japan
-
- Furusyo Norihiro
- Department of General Internal Medicine, Kyushu University Hospital, Japan
-
- Nakamuta Makoto
- Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Japan
-
- Kajiwara Eiji
- Department of Hepatology, Steel Memorial Yawata Hospital, Japan
-
- Dohmen Kazufumi
- Department of Internal Medicine, Chihaya Hospital, Japan
-
- Nomura Hideyuki
- The Center for Liver Disease, Shin-Kokura Hospital, Japan
-
- Takahashi Kazuhiro
- Department of Medicine, Hamanomachi Hospital, Japan
-
- Satoh Takeaki
- Center for Liver Disease, National Hospital Organization Kokura Medical Center, Japan
-
- Azuma Koichi
- Department of Medicine, Kyushu Central Hospital, Japan
-
- Tanabe Yuichi
- Department of Medicine, Fukuoka City Hospital, Japan
-
- Shimoda Shinji
- Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Kotoh Kazuhiro
- Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Hayashi Jun
- Department of General Internal Medicine, Kyushu University Hospital, Japan
この論文をさがす
抄録
Objective There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and on-treatment predictors of bacterial infections in patients treated with TVR-based triple therapy.<br> Methods This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria.<br> Results Bacterial infections occurred in 21 of the 430 (4.9%) patients during TVR-based triple therapy. Among these subjects, 71.4% (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8% of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1%) was significantly higher than that observed among men (1 of 215, 0.5%) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.0008). Of the 21 patients who experienced bacterial infections, only one (4.8%) had to discontinue the treatment; however, the others were able to continue anti-viral treatment in combination with antibiotic treatment.<br> Conclusion Clinicians should be concerned regarding the incidence of bacterial infections among patients treated with TVR-based triple therapy, especially those with a low serum albumin level.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 54 (6), 567-572, 2015
一般社団法人 日本内科学会
